Smart Cancer Guide

OneDayMD Editorial Team¹ | Independent Case Series Compilation ¹ The Medical Advisor, OneDayMD.com — Science-based Integrative Wellness Abstract Background: Cancer represents one of the leading causes of global morbidity and mortality. Advanced-stage (Stage IV) malignancies carry a poor prognosis with conventional therapies demonstrating 5-year survival rates as low as 13–26% across major cancer subtypes. The anti-parasitic benzimidazoles — fenbendazole (FBZ) and mebendazole (MBZ) — and the macrocyclic lactone ivermectin (IVM) have demonstrated plausible anti-neoplastic mechanisms in preclinical models, including disruption of tubulin polymerization, inhibition of glucose uptake, induction of apoptosis, and immunomodulation. However, robust clinical trial data in human oncology remain limited. Objective: To systematically compile, categorize, and critically appraise a large repository of patient-reported and physician-reported outcomes associated with...

Quick Answer “Cold” and “hot” tumors describe how visible a cancer is to the immune system. Hot tumors have strong immune cell infiltration and are more likely to respond to immunotherapy. Cold tumors lack immune visibility and are more resistant. However, recent research shows this is an oversimplification. Tumors exist along a spectrum of immune states, shaped not only by genetics (PD-L1, TMB, MSI-H) but also by the tumor microenvironment, including immune exclusion, metabolism, and stromal barriers. Modern immunotherapy success depends on both tumor genetics and immune ecosystem structure. Key Takeaways Tumors are not simply “cold” or “hot” but exist on an immune spectrum. Hot tumors usually respond better to PD-1/PD-L1 checkpoint inhibitors. Cold tumors often resist immunotherapy due to lack of immune infiltration. Immune-excluded tumors have immune cells at the edges but not inside. Immune-desert tumors lack meaningful immune presence entirely. ...

In the evolving healthcare landscape of 2026, cancer is no longer viewed solely through a genetic lens. It is recognized as a complex, adaptive ecosystem that is simultaneously genetic, metabolic, immunological, and ecological. While standard treatments remain the core foundation, the integration of metabolic oncology has become essential for addressing the "downstream manifestations" of genetic mutations. The Metabolic Debate: Warburg vs. OXPHOS The metabolic theory of cancer, popularized by Professor Tom Seyfried , focuses on Otto Warburg’s discovery that cancer cells prefer aerobic glycolysis (fermentation) due to mitochondrial dysfunction. Seyfried’s "Press-Pulse" strategy seeks to "starve" these cells by restricting glucose and glutamine while pulsing with metabolic inhibitors. However, 2026 expert Jane McLelland highlights a critical "blind spot": not all cancers are glycolytic . Many common tumors, such as ER+ breast canc...

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest human malignancies, with a five-year survival rate stubbornly below 15% despite decades of advances in surgery, chemotherapy, and molecular oncology. Most discussions focus on late diagnosis, aggressive genetics, or therapeutic resistance. Far less attention is paid to a quieter but increasingly evident factor: insulin resistance and metabolic dysfunction . Emerging evidence suggests that pancreatic cancer is not merely influenced by metabolic disease—it may be deeply intertwined with it . Insulin resistance often precedes diagnosis, worsens prognosis, and biologically fuels tumor growth. Yet it remains largely absent from staging systems, risk stratification, and treatment frameworks. A 2023 study from researchers at University of British Columbia’s Faculty of Medicine reveals a direct link between high insulin levels, common among patients with obesity and type 2 diabetes, and pancreatic cancer. The study, published...

The global oncology market has entered a dynamic new phase in 2026—defined by immunotherapy dominance, rapid CAR-T expansion, and next-generation targeted delivery mechanisms. While legacy pharmaceutical giants still command massive baseline revenues, financial and clinical data from the first half of 2026 reveal a clear shift: long-term survival in this sector requires aggressive platform M&A activity, companion diagnostics, and defense strategies against upcoming patent cliffs. This comprehensively updated 2026 analysis breaks down the leading oncology drug companies, evaluating them by revenue performance, core pipeline assets, and their strategic resilience against market pressures. 2026 Landscape: Top Oncology Revenue Drivers at a Glance Company Flagship Oncology Asset Primary 2026 Strategic Focus Looming Headwind Merck & Co. (MRK) Keytruda (pembrolizumab) Co-formula...

Cancer treatment has changed dramatically over the past few decades. For much of modern medical history, chemotherapy was the primary systemic therapy used to treat cancer. Today, immunotherapy is transforming the field of oncology by enabling the immune system to recognize and attack cancer cells. Patients newly diagnosed with cancer often face a confusing array of treatment options. Many ask important questions such as: Is immunotherapy better than chemotherapy? What are the risks and benefits of each treatment? Which cancers respond best to immunotherapy? Can these therapies be combined? What happens if immunotherapy fails? Understanding the differences between chemotherapy and immunotherapy can help patients make more informed decisions together with their healthcare providers. This comprehensive guide explains how these treatments work, their effectiveness, side effects, survival outcomes, costs, and emerging innovations in cancer therapy. Credit:  Statista What Is Chemother...